1. Most Discussed
  2. Gainers & Losers
PBT 4.6¢

PBT1033 - development

  1. interestingtome

    1,847 Posts.
    1
    Thought you guys would be interested in this thread from ymb
    Originally posted by kadaicher1 • 5 hours ago

    2 users liked this posts users disliked this posts 2
    Reply

    What is this?
    [Clinical Development of PBT 1033
    1033 was administered to healthy volunteers in a 2-part study comprising single dose administration (Stage A) and multidose administration (Stage B). Overall, 1033 was generally well tolerated as a single dose in young male volunteers and up to 7 days of treatment in elderly healthy volunteers.

    The objectives of the following trials were to determine the safety, tolerability and pharmacokinetics of single and multiple oral doses of 1033 in healthy volunteers. Double-blind studies were conducted. The protocol included safety measures designed to capture the potential human adverse effects. A total of 65 healthy subjects have been exposed to doses of 1033 (41 single dose, 24 multiple dose).]

    interestingtome • 20 minutes ago Remove
    J is correct. This was listed in an earlier patent but here's a summary of results.

    The patent information shows that PBT1033 was selected for advancement up through human clinical testing. PBT1033 exhibited one of the highest AB inhibition rates at 38% as shown in Table 7 It also exhibited a 37% soluble and 29% insoluble AB change rate in the transgenic mouse brain models with greater than 50% BBB penetration. Mean plaque removals were higher than PBT1038, 1051 and 1052.

    The compound was tested in Transgenic HD mice with favorable results prior to clinical testing for safety and tolerability at dosing levels up to 800 mg. Treated mice exhibited significant improvement in rotarod performance, clasping behavior (typical in HD mice), greater body weights, longer life spans, ventricle areas, brain weight and Htt protein aggregates were not detected in treated mice.

    PBT1033 was also tested against glioma cells (brain cancer). The results shown indicate a dose-related reduction in tumor area in mice with most effective reduction at 100 mg dose.

    The clinical testing in humans raised by Kad is interesting indicating safe and tolerable dosing up to 800 mg in healthy elderly humans.

    Here's the conclusion "It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and the methods described herein may be made without departing form the scope of the inventive concept disclosed in this specification." More compound tinkering to come.

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.